Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial.

被引：0
|
作者：
Qin, Shukui
Bai, Yuxian
Wang, Zishu
Chen, Zhendong
Xu, Ruihua
Xu, Jianming
Zhang, Hongmei
Chen, Jia
Yuan, Ying
Liu, Tianshu
Yang, Lin
Zhong, Haijun
Chen, Donghui
Shen, Lin
Hao, Chunyi
Fu, Deliang
Cheng, Ying
Yang, Jianwei
Bai, Xian Hong
Li, Jin
机构：
[1] Jinling Hosp, Ctr Canc, Dept Med Oncol, Nanjing, Peoples R China
[2] Harbin Med Univ Canc Hosp, Harbin, Peoples R China
[3] Bengbu Med Coll, Affiliated Hosp 1, Bengbu, Peoples R China
[4] Anhui Med Univ, Hosp 2, Hefei, Anhui, Peoples R China
[5] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou, Peoples R China
[6] Gen Hosp Peoples Liberat Army, Dept Gastrointestinal Oncol, Med Ctr 5, Beijing, Peoples R China
[7] Air Force Med Univ PLA, Xijing Hosp, Xian, Peoples R China
[8] Jiangsu Canc Hosp, Dept Oncol, Nanjing, Peoples R China
[9] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Med Oncol, Hangzhou, Peoples R China
[10] Fudan Univ, Zhongshan Hosp, Dept Med Oncol, Shanghai, Peoples R China
[11] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China
[12] Univ Chinese Acad Sci, Chinese Acad Sci, Dept Med Oncol, Zhejiang Canc Hosp,Inst Canc & Basic Med,Canc Hos, Hangzhou, Peoples R China
[13] Shanghai Jiao Tong Univ, Peoples Hosp 1, Sch Med, Dept Oncol, Shanghai, Peoples R China
[14] Peking Univ Canc Hosp & Inst, Minist Educ Beijing, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China
[15] Beijing Canc Hosp, Beijing, Peoples R China
[16] Fudan Univ, Pancreat Dis Inst, Huashan Hosp, Dept Pancreat Surg, Shanghai, Peoples R China
[17] Jilin Canc Hosp, Dept Med Thorac Oncol, Changchun, Peoples R China
[18] Fujian Med Univ Canc Hosp, Fujian Canc Hosp, Dept Abdominal Oncol, Fuzhou, Peoples R China
[19] Biotech Pharmaceut Ltd Corp, Beijing, Peoples R China
[20] Shanghai East Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA4011
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase II randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of simtuzumab (GS-6624) combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
    Benson, Al Bowen
    Thai, Zung
    Hawkins, Michael J.
    Werner, Douglas
    Dong, Hua
    Lee, Claudia
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [42] Randomized, cross-over phase III study of gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer - a multicenter trial of the "Arbeitsgemeinschaft Internistische Onkologie" (AIO)
    Boeck, S.
    Vehling-Kaiser, U.
    Waldschmidt, D.
    Kettner, E.
    Maerten, A.
    Winkelmann, C.
    Klein, S.
    Kojouharoff, G.
    Jung, A.
    Heinemann, V
    ONKOLOGIE, 2010, 33 : 25 - 25
  • [43] Phase II/III clinical trial with VEGFR2-epitope peptide and gemcitabine for patients with locally advanced, metastatic, or unresectable pancreatic cancer: Pegasus-PC study
    Yamaue, Hiroki
    Tani, Masaji
    Miyazawa, Motoki
    Yamao, Kenji
    Mizuno, Nobumasa
    Okusaka, Takuji
    Ueno, Hideki
    Boku, Narikazu
    Fukutomi, Akira
    Ishii, Hiroshi
    Ohkawa, Shinichi
    Furukawa, Masayuki
    Maguchi, Hiroyuki
    Ikeda, Masafumi
    Nishio, Kazuto
    Ohashi, Yasuo
    Tsunoda, Takuya
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [44] A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer
    Treat, J. A.
    Gonin, R.
    Socinski, M. A.
    Edelman, M. J.
    Catalano, R. B.
    Marinucci, D. M.
    Ansari, R.
    Gillenwater, H. H.
    Rowland, K. M.
    Comis, R. L.
    Obasaju, C. K.
    Belani, C. P.
    ANNALS OF ONCOLOGY, 2010, 21 (03) : 540 - 547
  • [45] MISTLETOE EXTRACT THERAPY VERSUS NO ANTINEOPLASTIC THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER: A RANDOMIZED CLINICAL PHASE III TRIAL ON OVERALL SURVIVAL
    Galun, D.
    Troeger, W.
    Reif, M.
    Schumann, A.
    Stankovic, N.
    Milicevic, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 237 - 237
  • [46] A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol
    He, Jinjie
    Liu, Yue
    Liu, Chengcheng
    Hu, Hanguang
    Sun, Lifeng
    Xu, Dong
    Li, Jun
    Wang, Junye
    Chen, Xiaobing
    Lin, Rongbo
    Jiang, Yi
    Zhang, Yanqiao
    Zhang, Weisheng
    Cheng, Ying
    Wu, Xiaohong
    Fang, Mingzhi
    Li, Enxiao
    Xu, Ye
    Chen, Ye
    Li, Jiayi
    Cui, Yanyan
    Pan, Zhanyu
    Zhang, Songnan
    Yuan, Ying
    Ding, Kefeng
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [47] A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol
    He, Jinjie
    Liu, Yue
    Liu, Chengcheng
    Hu, Hanguang
    Sun, Lifeng
    Xu, Dong
    Li, Jun
    Wang, Junye
    Chen, Xiaobing
    Lin, Rongbo
    Jiang, Yi
    Zhang, Yanqiao
    Zhang, Weisheng
    Cheng, Ying
    Wu, Xiaohong
    Fang, Mingzhi
    Li, Enxiao
    Xu, Ye
    Chen, Ye
    Li, Jiayi
    Cui, Yanyan
    Pan, Zhanyu
    Zhang, Songnan
    Yuan, Ying
    Ding, Kefeng
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [48] A randomized controlled, open label, adaptive phase III Trial to evaluate safety and efficacy of endoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment
    Chen, L-T.
    Hitre, E.
    Lee, W-J.
    Bai, L-Y.
    Papai, Z.
    Kang, S. Y.
    Dvorkin, M.
    Choi, H. J.
    Oh, S. C.
    Artru, P.
    Bachet, J-B.
    ANNALS OF ONCOLOGY, 2019, 30 : 321 - 321
  • [49] A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer
    Vervenne, W.
    Bennouna, J.
    Humblet, Y.
    Gill, S.
    Moore, M. J.
    Van Laethem, J.
    Shang, A.
    Cosaert, J.
    Verslype, C.
    Van Cutsem, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [50] A double-blinded, placebo-controlled, randomized, phase III study of axitinib (AG-013736; A) plus gemcitabine (G) vs. G plus placebo (P) in advanced pancreatic cancer (PC) patients (pts)
    Kindler, H. L.
    Ioka, T.
    Richel, D. J.
    Bennouna, J.
    Letourneau, R.
    Okusaka, T.
    Bycott, P.
    Ricart, A. D.
    Kim, S.
    Van Cutsem, E.
    EJC SUPPLEMENTS, 2009, 7 (02): : 361 - 362
12345